Basis: FMP quote price / unrounded diluted EPS from four consecutive issuer fiscal quarters. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the P/E ratio high or low?
The P/E ratio of 0.85 is 25% below its 1-year average of 1.13, near the low end of its 1-year range (0.83–1.43).
As of 2026-10-06T16:41:57.141Z.
Calculation as of: 2026-10-06T16:41:57.141Z.
Quote observation: 2026-10-06T16:37:25.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: b5b90a83151b8a074e07f32cd5a8423240b7dae761ecc8f52934664174c7f924
PE Ratio (0.85) = Close Price ($0.80) / Diluted TTM EPS ($0.94)
PE RATIO
0.85
PE RATIO AVG TTM
N/A
PE RATIO AVG 3Y
N/A
PE RATIO AVG 5Y
N/A
PE RATIO AVG 10Y
N/A
PE RATIO AVG 15Y
N/A
PE RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
25.49
median of 175 covered companies
CURRENT VS SECTOR MEDIAN
-96.67%
vs the sector median at left
| NAME | MARKET CAP | PE RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Elutia Inc (ELUT) | $35.15M | 0.85 | N/A | N/A | N/A |
| BriaCell Therapeutics Corp. (BCTX)vs › | $35.10M | N/A | N/A | N/A | N/A |
| Grace Therapeutics, Inc. (GRCE)vs › | $34.34M | N/A | N/A | N/A | N/A |
| DocGo Inc. (DCGO)vs › | $35.76M | N/A | 14.70 | 37.22 | 37.36 |
| Accuray Incorporated (ARAY)vs › | $34.04M | N/A | 241.49 | 241.49 | 115.68 |
| Elicio Therapeutics, Inc. (ELTX)vs › | $36.61M | N/A | N/A | N/A | N/A |
| QT Imaging Holdings, Inc. (QTI)vs › | $36.76M | N/A | N/A | N/A | N/A |
| Aligos Therapeutics, Inc. (ALGS)vs › | $33.79M | N/A | N/A | N/A | N/A |
| Edesa Biotech, Inc. (EDSA)vs › | $37.67M | N/A | N/A | N/A | N/A |
| EUDA Health Holdings Limited (EUDA)vs › | $32.91M | N/A | N/A | N/A | N/A |
At 0.8, P/E is below its 1-year median — higher than 6% of readings in its 1-year history.
1-year low
0.8
median
1.1
1-year high
1.4
Trailing P/E
0.8
Forward P/E
N/A
Forward P/E is calculated using analyst consensus EPS estimates for the current or next fiscal year.
Calculation:
Current Price
$0.80
Forward EPS (Est.)
$-0.63
Forward P/E
N/A
Source: FMP Analyst Consensus Estimates. Forward EPS represents the average analyst estimate for the nearest fiscal year.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | PE RATIO |
|---|---|
| 2026-10-05 | 0.87 |
| 2026-10-02 | 0.83 |
| 2026-10-01 | 0.85 |
| 2026-09-30 | 0.84 |
| 2026-09-29 | 0.84 |
| 2026-09-28 | 0.86 |
| 2026-09-25 | 0.87 |
| 2026-09-24 | 0.88 |
| 2026-09-23 | 0.92 |
| 2026-09-22 | 0.86 |
| 2026-09-21 | 0.91 |
| 2026-09-18 | 0.90 |
| 2026-09-17 | 0.90 |
| 2026-09-16 | 0.86 |
| 2026-09-15 | 0.85 |
| 2026-09-14 | 0.84 |
| 2026-09-11 | 0.86 |
| 2026-09-10 | 0.85 |
| 2026-09-09 | 0.85 |
| 2026-09-08 | 0.88 |
| 2026-09-04 | 0.87 |
| 2026-09-03 | 0.89 |
| 2026-09-02 | 0.90 |
| 2026-09-01 | 0.92 |
| 2026-08-31 | 0.92 |
| 2026-08-28 | 0.94 |
| 2026-08-27 | 0.94 |
| 2026-08-26 | 1.06 |
| 2026-08-25 | 1.07 |
| 2026-08-24 | 1.02 |
| 2026-08-21 | 1.01 |
| 2026-08-20 | 0.96 |
| 2026-08-19 | 0.98 |
| 2026-08-18 | 0.97 |
| 2026-08-17 | 1.04 |
| 2026-08-14 | 1.09 |
| 2026-08-13 | 1.00 |
| 2026-08-12 | 0.95 |
| 2026-08-11 | 0.93 |
| 2026-08-10 | 0.95 |
| 2026-08-07 | 0.99 |
| 2026-08-06 | 1.02 |
| 2026-08-05 | 1.01 |
| 2026-08-04 | 1.01 |
| 2026-08-03 | 1.01 |
| 2026-07-31 | 1.00 |
| 2026-07-30 | 1.05 |
| 2026-07-29 | 1.02 |
| 2026-07-28 | 1.06 |
| 2026-07-27 | 1.12 |
| 2026-07-24 | 1.08 |
| 2026-07-23 | 1.08 |
| 2026-07-22 | 1.08 |
| 2026-07-21 | 1.10 |
| 2026-07-20 | 1.08 |
| 2026-07-17 | 1.10 |
| 2026-07-16 | 1.10 |
| 2026-07-15 | 1.12 |
| 2026-07-14 | 1.06 |
| 2026-07-13 | 1.06 |
| 2026-07-10 | 1.12 |
| 2026-07-09 | 1.13 |
| 2026-07-08 | 1.10 |
| 2026-07-07 | 1.12 |
| 2026-07-06 | 1.10 |
| 2026-07-02 | 1.08 |
| 2026-07-01 | 1.10 |
| 2026-06-30 | 1.14 |
| 2026-06-29 | 1.11 |
| 2026-06-26 | 1.16 |
| 2026-06-25 | 1.10 |
| 2026-06-24 | 1.14 |
| 2026-06-23 | 1.20 |
| 2026-06-22 | 1.16 |
| 2026-06-18 | 1.23 |
| 2026-06-17 | 1.15 |
| 2026-06-16 | 1.10 |
| 2026-06-15 | 1.13 |
| 2026-06-12 | 1.12 |
| 2026-06-11 | 1.11 |
| 2026-06-10 | 1.21 |
| 2026-06-09 | 1.13 |
| 2026-06-08 | 1.15 |
| 2026-06-05 | 1.16 |
| 2026-06-04 | 1.22 |
| 2026-06-03 | 1.15 |
| 2026-06-02 | 1.21 |
| 2026-06-01 | 1.23 |
| 2026-05-29 | 1.35 |
| 2026-05-28 | 1.30 |
| 2026-05-27 | 1.31 |
| 2026-05-26 | 1.33 |
| 2026-05-22 | 1.35 |
| 2026-05-21 | 1.40 |
| 2026-05-20 | 1.37 |
| 2026-05-19 | 1.30 |
| 2026-05-18 | 1.28 |
| 2026-05-15 | 1.26 |
| 2026-05-14 | 1.27 |
| 2026-05-13 | 1.28 |
| 2026-05-12 | 1.28 |
| 2026-05-11 | 1.29 |
| 2026-05-08 | 1.23 |
| 2026-05-07 | 1.22 |
| 2026-05-06 | 1.24 |
| 2026-05-05 | 1.19 |
| 2026-05-04 | 1.23 |
| 2026-05-01 | 1.23 |
| 2026-04-30 | 1.24 |
| 2026-04-29 | 1.22 |
| 2026-04-28 | 1.22 |
| 2026-04-27 | 1.24 |
| 2026-04-24 | 1.30 |
| 2026-04-23 | 1.33 |
| 2026-04-22 | 1.40 |
| 2026-04-21 | 1.43 |
| 2026-04-20 | 1.37 |
| 2026-04-17 | 1.40 |
| 2026-04-16 | 1.43 |
| 2026-04-15 | 1.43 |
| 2026-04-14 | 1.39 |
| 2026-04-13 | 1.34 |
| 2026-04-10 | 1.38 |
| 2026-04-09 | 1.38 |
| 2026-04-08 | 1.39 |
| 2026-04-07 | 1.41 |
| 2026-04-06 | 1.41 |
| 2026-04-02 | 1.43 |
| 2026-04-01 | 1.33 |
| 2026-03-31 | 1.28 |
| 2026-03-30 | 1.28 |
| 2026-03-27 | 1.30 |
| 2026-03-26 | 1.30 |
| 2026-03-25 | 1.37 |
| 2026-03-24 | 1.29 |
| 2026-03-23 | 1.35 |
| 2026-03-20 | 1.34 |
| 2026-03-19 | 1.28 |
| 2026-03-18 | 1.32 |
| 2026-03-17 | 1.33 |
| 2026-03-16 | 1.30 |